Reversible Optic Nerve Conduction Recovery After Teprotumumab in Dysthyroid Optic Neuropathy: Longitudinal Visual Evoked Potential Findings
This case report demonstrates that teprotumumab therapy in a patient with dysthyroid optic neuropathy led to significant clinical and electrophysiologic recovery, evidenced by the normalization of visual acuity and the reversal of delayed visual evoked potential latencies, supporting serial VEP assessment as an objective biomarker for treatment response.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your eyes are like two high-speed fiber-optic cables sending pictures to your brain's control center. Now, picture a 91-year-old woman whose left cable got squished. It wasn't a kink in the wire; it was like someone had packed her eye socket so tight with swollen muscles and inflammation that the cable was being squeezed at the very back, near the "apex" of the socket. This condition is called Dysthyroid Optic Neuropathy (DON), and it was turning her vision into a fuzzy, dim static.
Her eye doctor, acting like a detective, found some very specific clues. Her left eye could only see 0.05 on a vision chart (basically, she could barely make out shapes), while her right eye was doing much better at 0.6. But the real "smoking gun" came from a test called a Visual Evoked Potential (VEP). Think of the VEP as a stopwatch that measures how fast an electrical signal travels down that optic cable. In a healthy eye, the signal zips along quickly. In this patient's left eye, the signal was dragging its feet, taking a sluggish 135 milliseconds to arrive, and the signal itself was weak, only 3.1 µV. It was a classic sign of a compressed nerve.
The doctors decided to try a new kind of medicine called teprotumumab. You can think of this drug as a "deflator" for the eye socket. It works by telling the swollen muscles to stop growing and to shrink back down, relieving the pressure on the squished cable.
The results were like watching a traffic jam slowly clear up. After just three doses of the medicine, things started to look brighter. Her vision in the left eye jumped from 0.05 to 0.15, and the "stopwatch" on her nerve signal started to tick faster. But the real magic happened after she received eight infusions in total.
By the end of the treatment, the swelling had gone down so much that her eye popped out less (proptosis dropped from 19 mm to 13 mm), and her vision in the left eye recovered to 0.6. But here is the coolest part: the VEP test showed that the electrical signal was almost back to normal speed and strength. The sluggish 135 ms delay was gone, and the signal amplitude bounced back. The "traffic jam" had cleared, and the cable was conducting electricity smoothly again.
This paper suggests that teprotumumab didn't just make her look better or see better; it actually helped the physical nerve recover its ability to conduct signals. The authors point out that while some people think these electrical tests aren't great for diagnosing the problem right at the start (because sometimes the test looks normal even when the eye is in trouble), this case shows they are fantastic for watching the recovery. It's like having a dashboard light that tells you exactly when the engine is running smoothly again.
The paper is careful to say this is just one story from one patient, so we can't say for sure this works for everyone yet. They didn't prove it's a cure-all, but they did measure a clear, step-by-step improvement in how the nerve worked as the medicine did its job. It suggests that checking these electrical signals over time could be a really useful way to see if the treatment is actually fixing the nerve, not just the swelling.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.